A Phase 2 interventional study of OPDC-34712 and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-02-02.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd. — 5 open to participants now, 5 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · Otsuka Holdings Co., Ltd..
Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., this one has the largest enrollment, is the only one that started in 2010, is one of 5 in phase 2, and was the 1st registered.
1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →5 of the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
By country, each count listing its studies:
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 12
First in 2010; this study’s year is marked. 1 started in 2010.
This study's enrollment of 740 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 180 across the 25 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
3 of the studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT07087327Phase 3Otsuka Pharmaceutical Co., Ltd.A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
| NCT07086313Phase 3Otsuka Pharmaceutical Co., Ltd.A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact on sleep, quality of life and cognitive function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for 5 weeks. Once assigned to a stimulant by the investigator, participants remained on the same stimulant for the duration of the trial. Participants who met eligibility criteria i.e., who received prior treatment for adult ADHD and treatment-naïve participants were included in this arm group. Participants with incomplete response at the end of Phase A (Week 5) entered Phase B and rest of the participants continued to Phase A+.
Drug: Placebo · Drug: Stimulant Therapy
Participants with incomplete response (with a \> 0% and \< 30% reduction in ADHD Symptoms Total Score {18 items} between the baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV { Conners' Adult ADHD Rating Scale-Observer: Screening Version}, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a clinical global impression - improvement scale (CGI-I) score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received Brexpiprazole 2 milligram (mg) tablet along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
Drug: OPDC-34712 · Drug: Stimulant Therapy
Participants with incomplete response (with a \> 0% and \< 30% reduction in ADHD Symptoms Total Score {18 items} between the Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, and a CAARS-O:SV ADHD Symptoms Total Score {18 items} of ≥ 24 at Week 5, and a CGI-I score of 3 or 4 at Week 5) at the end of Phase A (Week 5), received matching-placebo tablets along with stimulant determined by the investigator, once daily for 6 weeks (up to Week 11).
Drug: Placebo · Drug: Stimulant Therapy
Participants with response (with a ≥ 30% reduction in ADHD Symptoms Total Score {18 items} between Baseline of Phase A and the end of prospective treatment { Week 5} as measured by the CAARS-O:SV, or a CAARS-O:SV ADHD Symptoms Total Score {18 items} of \< 24 at Week 5, or a CGI-I score of \< 3 at Week 5) and non-response (with deterioration or no change in ADHD symptoms at Week 5) at the end of Phase A (Week 5), received single-blind matching-placebo tablets along with open-label stimulant determined by the investigator, once daily for an additional 6 weeks (up to Week 11).
Drug: Placebo · Drug: Stimulant Therapy
OPDC-34712 tablets, daily, Orally.
Also known as: Brexpiprazole
Matching-placebo tablets, daily, Orally.
Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B
The CAARS-O:SV is a 30 items scale with 3 subscales: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Inattentive Symptoms (9 items), DSM- IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The Mixed model repeated measures (MMRM) model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score to End of Phase B
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present) and summarized each of the 7 categories on a 0-to-4 scale (0=none, 1=mild, 2=moderate, 3=quite a bit, 4=very much). The WRAADDS total score is defined as sum of all 28 item sub scores (range 0 - 56), higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The analysis of covariance (ANCOVA) method was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in Sleep Improvement Measured by Insomnia Severity Index (ISI) Total Score to End of Phase B
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in Sleep Improvement Measured by ISI for Item 2 Score (Difficulty Staying Asleep) to End of Phase B
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in the Spatial Working Memory (SWM) Between Errors 4-8 Boxes Test Score as Measured by Cambridge Neuropsychological Test Automated Battery (CANTAB) to End of Phase B
ADHD was measured with the CANTAB. SWM test was one of the tasks of CANTAB, SWM measured the ability to retain spatial information and to manipulate remembered items in working memory. This test was sensitive measure of executive dysfunction. Participants search for colored tokens hidden inside boxes on screen by touching them. The critical instruction was that once token has been found inside box, no token was hidden inside that box again, so participants must not return to box where a token was found. The key measurement of the SWM task is the SWM Between Errors 4-8 Boxes, which measured the total number of times a participant revisits a box in which a token has previously been found is measured for the 4, 6, and 8-box stages. Total scores ranged from 0-153. A lower score indicated better performance. The ANCOVA model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in CAARS-O:SV ADHD Symptoms Total Score (18 Items) to Each Time Point in Phase B Other Than Week 11
The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Weeks 6, 7, 8, 9 and 10
Change From Baseline (End of Phase A) in CAARS-O:SV Inattentive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B
The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The inattentive symptoms subscale (9 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) in CAARS-O:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Time Point in Phase B
The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The hyperactive/impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) in CAARS-O:SV ADHD Index Score (12 Items) to Each Time Point in Phase B
The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD index score (12 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) to Weeks 7 and 9 in ISI Total Score
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 7 and 9
Percentage of Participants With Categorical Change in Sleep Improvement Measured by Individual Scores for Items 1, 2, and 3 of the ISI at End of Phase B
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity. difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A negative change from Baseline indicates improvement. The Cochran-Mantel-Haenszel model was used for analysis.
Time frame: Baseline [(end of Phase A (Week 5)] to Weeks 7, 9 and 11
Change From Baseline (End of Phase A) in Conners' Adult ADHD Rating Scale-Self-Report: Screening Version (CAARS-S:SV) ADHD Symptoms Total Score (18 Items) to Each Timepoint in Phase B
The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) in CAARS-S:SV Inattentive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B
The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Inattentive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) in CAARS-S:SV Hyperactive/Impulsive Symptoms Subscale Score (9 Items) to Each Timepoint in Phase B
The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Hyperactive/Impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) in CAARS-S:SV ADHD Index Score (12 Items) to Each Timepoint in Phase B
The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD Index Subscale is (12 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score to Each Timepoint in Phase B
The CGI-S is performed to rate the severity of a participant's condition on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)]; Weeks 6, 7, 8, 9, 10 and 11
Change From Baseline (End of Phase A) in the SWM Strategy 6-8 Boxes Test Score as Measured by CANTAB to End of Phase B
The SWM test assesses the cognitive domain of executive function (high-level thinking and decision making). SWM task was SWM Strategy 6-8 Boxes, in which the total number of distinct boxes used by the participant to begin a new search for a token within the same problem was measured for the 6- and 8-box stages. The SWM strategy index of executive function represented the number of times a participant began a search with a different box. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments. Strategy score was the number of unique boxes the participant searched in 6 and 8 box trials. 6 box trial scores ranged from 1 (1 box searched for all 6 tokens) to 6 (6 boxes searched for 6 tokens). 8 box trial score ranged from 1 (1 box searched) to 8 (8 boxes searched for 8 tokens). Total of the 2 trial scores ranged from 2 to 14. A lower score reflects better performance. The ANCOVA method was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in the SWM Within Errors 4-8 Boxes Test Score as Measured by CANTAB to End of Phase B
Assessments were performed with CANTAB. SWM test assesses cognitive domain of executive function (high-level thinking and decision making). Participants search for colored tokens hidden inside boxes on screen by touching them. Critical instruction is that once a token has been found inside a box, there was never be a token hidden inside that box again, so participants must not return to a box where a token has been found. Within Errors 4-8 Boxes, which measured number of times a participant revisited a box that had already been found to be empty during the same search. Value was reported as total number of errors for 4-, 6-, and 8-box stages. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -8.00 to 6.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -10.0 to 23.00 (change from baseline). A lower score reflects better performance. LOCF method was used to impute missing data.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in the Rapid Visual Information Processing (RVP) A Prime Test Score as Measured by CANTAB to End of Phase B
Assessments were performed with the CANTAB. The RVP task tested continuous performance and visual sustained attention. In the center of the computer screen, digits from 2 to 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch the press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from the RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. RVP A prime was the signal detection measure of sensitivity to the target, regardless of response tendency (range 0.00 to 1.00; bad to good). In essence, this metric was a measure of how good the participant was at detecting target sequences. Higher scores indicated better performance. The ANCOVA method was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in the RVP Median Response Latency Score as Measured by CANTAB to End of Phase B
Assessments were performed with CANTAB. RVP task tested continuous performance and visual sustained attention. In the center of computer screen, digits from 2 to 9 appear inside white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. Median response latency was measured during the assessed part of test (7-minute continuous part of test after initial 2 minutes training phase). Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -338 to 282.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -134 to 235.0 (change from baseline). Lower scores indicate better performance. ANCOVA method was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in RVP Total False Alarms Score as Measured by CANTAB to End of Phase B
RVP task tested continuous performance and visual sustained attention. In center of computer screen, digits from 2- 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (e.g., 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. False alarms were determined from number of times that participants responded outside response window of a target sequence during assessed part of test. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -26.0 to 13.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -25.0 to 144.0 (change from baseline). Lower scores indicate better performance. ANCOVA model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in the Stop Signal Task (SST) Stop Signal Reaction Time (SSRT) Score as Measured by CANTAB to End of Phase B
In SST, an arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited response. Proportion of successful stops, and median reaction time on Go trials was measured. SST SSRT was an estimate of length of time between go stimulus and stop stimulus at which participant was able to successfully inhibit response on 50% of trials and calculated from SST reaction time on Go trials measure and SST stop signal delay (SSD) 50% measure as \[reaction time on Go trials\] - \[SSD (50%)\], where SSD (50%) measure was calculated as arithmetic mean of measured SSD, or failed stop reaction time, from completed assessment stop trials. Observed change from baseline range for Phase B: Brexpiprazole + Stimulant: -204 to 237.0 and for Phase B: Placebo + Stimulant: -176 to 113.0. Lower scores indicate better performance.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in the SST Proportion of Successful Stops Score as Measured by CANTAB to End of Phase B
SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The proportion of successful stops is calculated as the number of times that the participant stopped successfully, divided by the total number of stop signals. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -0.40 to 0.40 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -0.38 to 0.38 (change from baseline). Higher scores indicate a positive outcome for proportion of successful stops.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in SST Median Reaction Time Score on Go Trials as Measured by CANTAB to End of Phase B
SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The median reaction time on Go trials is the median of the reaction time assessed on Go trials to which the participant responded correctly. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -277 to 266.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -462 to 358.0 (change from baseline). Lower scores indicate better performance.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in WRAADDS Attention + Organization Subscale Score to End of Phase B
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for attention + organization subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA method was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From End of Phase A (Week 5 Visit) to End of Phase B (Week 11 Visit) in WRAADDS Hyperactivity + Impulsivity Subscale Score to End of Phase B
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for hyperactivity + impulsivity subscale score ranges from 0-12, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Change From Baseline (End of Phase A) in WRAADDS Temper + Mood Lability + Emotional Over-reactivity Subscale Score to End of Phase B
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for temper + mood Lability + emotional over-reactivity subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.
Time frame: Baseline [end of Phase A (Week 5)] to Week 11
Mean CGI-I Score at Each Timepoint in Phase B
The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The CGI-I is completed by the clinician and assesses the participant's improvement relative to the symptoms at Baseline. The Cochran-Mantel-Haenszel model was used for analysis.
Time frame: Weeks 6, 7, 8, 9, 10 and 11
Percentage of Participants With CAARS-O:SV ADHD Symptoms Response Rate in Phase B
Response was defined as ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms.
Time frame: Weeks 6, 7, 8, 9, 10 and 11
Percentage of Participants With CAARS-O:SV ADHD Symptoms Remission Rate in Phase B
Remission was defined as CAARS-O:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.
Time frame: Weeks 6, 7, 8, 9, 10 and 11
Percentage of Participants With CAARS-S:SV ADHD Symptoms Response Rate in Phase B
Response was defined as ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.
Time frame: Weeks 6, 7, 8, 9, 10 and 11
Percentage of Participants With CAARS-S:SV ADHD Symptoms Remission Rate in Phase B
Remission was defined as CAARS-S:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.
Time frame: Weeks 6, 7, 8, 9, 10 and 11
Percentage of Participants With CGI-I Response Rate in Phase B
Response was defined as a CGI-I score of 1 or 2 (very much improved or much improved). The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The Cochran-Mantel-Haenszel model was used for analysis.
Time frame: Weeks 6, 7, 8, 9, 10 and 11
This study was conducted at 37 sites in United States from 16 Mar 2010 to 20 Jun 2011.
| Milestone | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant |
|---|---|---|---|---|
| Started | 740 | 0 | 0 | 0 |
| Analyzed for safety | 733 | 0 | 0 | 0 |
| Completed | 574 | 0 | 0 | 0 |
| Not completed | 166 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 16 | 0 | 0 | 0 |
| Withdrew: Adverse event | 51 | 0 | 0 | 0 |
| Withdrew: Protocol specified withdrawal criteria | 47 | 0 | 0 | 0 |
| Withdrew: Withdrawn from participation by the investigator | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 32 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 10 | 0 | 0 | 0 |
| Withdrew: Participants not dosed | 7 | 0 | 0 | 0 |
| Milestone | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant |
|---|---|---|---|---|
| Started | 0 | 155 | 80 | 339 |
| Analyzed for safety | 0 | 155 | 80 | 235 |
| Completed | 0 | 146 | 70 | 314 |
| Not completed | 0 | 9 | 10 | 25 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 | 11 |
| Withdrew: Adverse event | 0 | 2 | 3 | 8 |
| Withdrew: Protocol-specified withdrawal criteria | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
The CAARS-O:SV is a 30 items scale with 3 subscales: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Inattentive Symptoms (9 items), DSM- IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The Mixed model repeated measures (MMRM) model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B | -9.02 ± 0.77 | -9.71 ± 1.06 |
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present) and summarized each of the 7 categories on a 0-to-4 scale (0=none, 1=mild, 2=moderate, 3=quite a bit, 4=very much). The WRAADDS total score is defined as sum of all 28 item sub scores (range 0 - 56), higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The analysis of covariance (ANCOVA) method was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score to End of Phase B | -3.93 ± 0.42 | -3.84 ± 0.56 |
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in Sleep Improvement Measured by Insomnia Severity Index (ISI) Total Score to End of Phase B | -1.05 ± 0.41 | -1.62 ± 0.56 |
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in Sleep Improvement Measured by ISI for Item 2 Score (Difficulty Staying Asleep) to End of Phase B | -0.04 ± 0.08 | -0.37 ± 0.10 |
ADHD was measured with the CANTAB. SWM test was one of the tasks of CANTAB, SWM measured the ability to retain spatial information and to manipulate remembered items in working memory. This test was sensitive measure of executive dysfunction. Participants search for colored tokens hidden inside boxes on screen by touching them. The critical instruction was that once token has been found inside box, no token was hidden inside that box again, so participants must not return to box where a token was found. The key measurement of the SWM task is the SWM Between Errors 4-8 Boxes, which measured the total number of times a participant revisits a box in which a token has previously been found is measured for the 4, 6, and 8-box stages. Total scores ranged from 0-153. A lower score indicated better performance. The ANCOVA model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in the Spatial Working Memory (SWM) Between Errors 4-8 Boxes Test Score as Measured by Cambridge Neuropsychological Test Automated Battery (CANTAB) to End of Phase B | 0.10 ± 0.67 | -0.31 ± 0.90 |
The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -3.82 ± 0.49 | -4.62 ± 0.64 |
| Change at Week 7 | -5.54 ± 0.58 | -6.21 ± 0.78 |
| Change at Week 8 | -6.37 ± 0.68 | -6.99 ± 0.92 |
| Change at Week 9 | -7.58 ± 0.71 | -8.14 ± 0.96 |
| Change at Week 10 | -7.71 ± 0.76 | -9.11 ± 1.04 |
The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The inattentive symptoms subscale (9 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -2.00 ± 0.32 | -2.43 ± 0.41 |
| Change at Week 7 | -2.94 ± 0.36 | -3.20 ± 0.48 |
| Change at Week 8 | -3.14 ± 0.40 | -3.42 ± 0.54 |
| Change at Week 9 | -3.74 ± 0.42 | -4.04 ± 0.57 |
| Change at Week 10 | -3.95 ± 0.45 | -4.85 ± 0.62 |
| Change at Week 11 | -4.58 ± 0.44 | -4.86 ± 0.60 |
The CAARS-O:SV is a 30 items scale with 3 subscales DSM-IV Inattentive Symptoms (9 items), DSM-IV Hyperactive/Impulsive Symptoms (9 items), and DSM-IV ADHD Index (12 items). The hyperactive/impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -1.88 ± 0.29 | -2.11 ± 0.38 |
| Change at Week 7 | -2.66 ± 0.32 | -2.94 ± 0.43 |
| Change at Week 8 | -3.29 ± 0.36 | -3.48 ± 0.49 |
| Change at Week 9 | -3.90 ± 0.39 | -4.01 ± 0.53 |
| Change at Week 10 | -3.83 ± 0.41 | -4.17 ± 0.55 |
| Change at Week 11 | -4.51 ± 0.42 | -4.80 ± 0.58 |
The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD index score (12 items) is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -2.06 ± 0.34 | -2.20 ± 0.44 |
| Change at Week 7 | -3.47 ± 0.41 | -3.38 ± 0.55 |
| Change at Week 8 | -4.01 ± 0.44 | -3.80 ± 0.59 |
| Change at Week 9 | -4.32 ± 0.46 | -4.78 ± 0.62 |
| Change at Week 10 | -4.65 ± 0.47 | -5.23 ± 0.64 |
| Change at Week 11 | -5.60 ± 0.48 | -5.94 ± 0.66 |
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A total score ranging from 0 to 28 was calculated from the sum of the individual item scores, higher scores indicate increased severity of insomnia. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 7 | -0.81 ± 0.33 | -0.83 ± 0.44 |
| Change at Week 9 | -0.99 ± 0.37 | -1.48 ± 0.49 |
The ISI is self-report instrument that has been validated specifically for measuring the perceived severity of insomnia. The scale was composed of a total of 7 items based on self-report questionnaire based on several indicators assessing the perceived severity. difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Each item was rated on a scale from 0 (none) to 4 (higher score indicating greater impairment/concern). A negative change from Baseline indicates improvement. The Cochran-Mantel-Haenszel model was used for analysis.
| percentage of participants | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Difficulty Falling Asleep: Week 7 | 33.6 | 32.4 |
| Difficulty Falling Asleep: Week 9 | 33.3 | 37.7 |
| Difficulty Falling Asleep: Week 11 | 35.3 | 39.0 |
| Difficulty Staying Asleep: Week 7 | 26.8 | 35.1 |
| Difficulty Staying Asleep: Week 9 | 25.3 | 33.8 |
| Difficulty Staying Asleep: Week 11 | 24.7 | 37.7 |
| Waking Up Too Early: Week 7 | 28.2 | 25.7 |
| Waking Up Too Early: Week 9 | 30.7 | 26.0 |
| Waking Up Too Early: Week 11 | 29.3 | 28.6 |
The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -1.75 ± 0.58 | -2.16 ± 0.75 |
| Change at Week 7 | -3.01 ± 0.65 | -3.47 ± 0.87 |
| Change at Week 8 | -4.15 ± 0.68 | -4.08 ± 0.92 |
| Change at Week 9 | -4.24 ± 0.73 | -5.23 ± 0.99 |
| Change at Week 10 | -4.63 ± 0.77 | -6.11 ± 1.04 |
| Change at Week 11 | -5.38 ± 0.78 | -6.33 ± 1.07 |
The CAARS-S:SV is a self-reported 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Inattentive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -0.87 ± 0.33 | -1.16 ± 0.43 |
| Change at Week 7 | -1.64 ± 0.37 | -1.62 ± 0.49 |
| Change at Week 8 | -2.08 ± 0.40 | -1.93 ± 0.54 |
| Change at Week 9 | -2.08 ± 0.42 | -2.42 ± 0.56 |
| Change at Week 10 | -2.43 ± 0.43 | -2.84 ± 0.58 |
| Change at Week 11 | -2.54 ± 0.43 | -3.10 ± 0.59 |
The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The Hyperactive/Impulsive Symptoms Subscale is (9 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 27, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -0.91 ± 0.32 | -1.06 ± 0.41 |
| Change at Week 7 | -1.38 ± 0.35 | -1.88 ± 0.47 |
| Change at Week 8 | -2.09 ± 0.36 | -2.20 ± 0.47 |
| Change at Week 9 | -2.18 ± 0.39 | -2.87 ± 0.52 |
| Change at Week 10 | -2.21 ± 0.41 | -3.33 ± 0.55 |
| Change at Week 11 | -2.86 ± 0.42 | -3.31 ± 0.57 |
The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). The ADHD Index Subscale is (12 items) scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) with total score ranging from 0 to 36, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -1.09 ± 0.37 | -1.16 ± 0.48 |
| Change at Week 7 | -1.86 ± 0.42 | -2.13 ± 0.55 |
| Change at Week 8 | -2.69 ± 0.44 | -2.43 ± 0.59 |
| Change at Week 9 | -3.07 ± 0.46 | -3.00 ± 0.61 |
| Change at Week 10 | -3.42 ± 0.47 | -3.56 ± 0.63 |
| Change at Week 11 | -4.05 ± 0.48 | -3.90 ± 0.65 |
The CGI-S is performed to rate the severity of a participant's condition on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. The MMRM model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change at Week 6 | -0.75 ± 0.06 | -0.71 ± 0.08 |
| Change at Week 7 | -0.92 ± 0.07 | -0.88 ± 0.09 |
| Change at Week 8 | -1.03 ± 0.07 | -0.97 ± 0.10 |
| Change at Week 9 | -1.16 ± 0.08 | -1.10 ± 0.11 |
| Change at Week 10 | -1.17 ± 0.08 | -1.28 ± 0.11 |
| Change at Week 11 | -1.31 ± 0.09 | -1.37 ± 0.12 |
The SWM test assesses the cognitive domain of executive function (high-level thinking and decision making). SWM task was SWM Strategy 6-8 Boxes, in which the total number of distinct boxes used by the participant to begin a new search for a token within the same problem was measured for the 6- and 8-box stages. The SWM strategy index of executive function represented the number of times a participant began a search with a different box. Participant was asked to find tokens in on-screen boxes and move them. Difficulty ranged from 4 to 8 box assessments. Strategy score was the number of unique boxes the participant searched in 6 and 8 box trials. 6 box trial scores ranged from 1 (1 box searched for all 6 tokens) to 6 (6 boxes searched for 6 tokens). 8 box trial score ranged from 1 (1 box searched) to 8 (8 boxes searched for 8 tokens). Total of the 2 trial scores ranged from 2 to 14. A lower score reflects better performance. The ANCOVA method was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in the SWM Strategy 6-8 Boxes Test Score as Measured by CANTAB to End of Phase B | 0.15 ± 0.21 | -0.12 ± 0.28 |
Assessments were performed with CANTAB. SWM test assesses cognitive domain of executive function (high-level thinking and decision making). Participants search for colored tokens hidden inside boxes on screen by touching them. Critical instruction is that once a token has been found inside a box, there was never be a token hidden inside that box again, so participants must not return to a box where a token has been found. Within Errors 4-8 Boxes, which measured number of times a participant revisited a box that had already been found to be empty during the same search. Value was reported as total number of errors for 4-, 6-, and 8-box stages. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -8.00 to 6.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -10.0 to 23.00 (change from baseline). A lower score reflects better performance. LOCF method was used to impute missing data.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in the SWM Within Errors 4-8 Boxes Test Score as Measured by CANTAB to End of Phase B | 0.00 ± 0.16 | 0.30 ± 0.22 |
Assessments were performed with the CANTAB. The RVP task tested continuous performance and visual sustained attention. In the center of the computer screen, digits from 2 to 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch the press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from the RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. RVP A prime was the signal detection measure of sensitivity to the target, regardless of response tendency (range 0.00 to 1.00; bad to good). In essence, this metric was a measure of how good the participant was at detecting target sequences. Higher scores indicated better performance. The ANCOVA method was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in the Rapid Visual Information Processing (RVP) A Prime Test Score as Measured by CANTAB to End of Phase B | 0.00 ± 0.00 | 0.01 ± 0.00 |
Assessments were performed with CANTAB. RVP task tested continuous performance and visual sustained attention. In the center of computer screen, digits from 2 to 9 appear inside white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (eg, 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. Median response latency was measured during the assessed part of test (7-minute continuous part of test after initial 2 minutes training phase). Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -338 to 282.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -134 to 235.0 (change from baseline). Lower scores indicate better performance. ANCOVA method was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in the RVP Median Response Latency Score as Measured by CANTAB to End of Phase B | -17.1 ± 5.36 | -2.89 ± 7.10 |
RVP task tested continuous performance and visual sustained attention. In center of computer screen, digits from 2- 9 appear inside a white box in pseudorandom order at a rate of 100 digits per minute. Participants must touch press pad when they detect a series of target digit sequences (e.g., 2-4-6, 4-6-8, 3-5-7) which appeared at a rate of 9 sequences every 100 numbers. Data from RVP task were summarized in 3 ways: RVP A prime, RVP median response latency, and RVP total false alarms. False alarms were determined from number of times that participants responded outside response window of a target sequence during assessed part of test. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant is -26.0 to 13.00 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant is -25.0 to 144.0 (change from baseline). Lower scores indicate better performance. ANCOVA model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in RVP Total False Alarms Score as Measured by CANTAB to End of Phase B | 0.12 ± 1.01 | 0.58 ± 1.34 |
In SST, an arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited response. Proportion of successful stops, and median reaction time on Go trials was measured. SST SSRT was an estimate of length of time between go stimulus and stop stimulus at which participant was able to successfully inhibit response on 50% of trials and calculated from SST reaction time on Go trials measure and SST stop signal delay (SSD) 50% measure as \[reaction time on Go trials\] - \[SSD (50%)\], where SSD (50%) measure was calculated as arithmetic mean of measured SSD, or failed stop reaction time, from completed assessment stop trials. Observed change from baseline range for Phase B: Brexpiprazole + Stimulant: -204 to 237.0 and for Phase B: Placebo + Stimulant: -176 to 113.0. Lower scores indicate better performance.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in the Stop Signal Task (SST) Stop Signal Reaction Time (SSRT) Score as Measured by CANTAB to End of Phase B | 13.41 ± 5.12 | -4.10 ± 6.92 |
SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The proportion of successful stops is calculated as the number of times that the participant stopped successfully, divided by the total number of stop signals. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -0.40 to 0.40 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -0.38 to 0.38 (change from baseline). Higher scores indicate a positive outcome for proportion of successful stops.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in the SST Proportion of Successful Stops Score as Measured by CANTAB to End of Phase B | -0.01 ± 0.01 | 0.01 ± 0.01 |
SST measures participants ability to inhibit a response. An arrow pointing either left or right is displayed on computer screen. Participant responded to arrow by pressing corresponding button (i.e., left or right) on press pad. If an audio tone is presented when arrow is displayed, participant inhibited his/her response. Proportion of successful stops, and median reaction time on Go trials was measured. The median reaction time on Go trials is the median of the reaction time assessed on Go trials to which the participant responded correctly. Observed range for Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant: -277 to 266.0 (change from baseline) and for Phase B (Double-blind Randomization Phase): Placebo + Stimulant: -462 to 358.0 (change from baseline). Lower scores indicate better performance.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in SST Median Reaction Time Score on Go Trials as Measured by CANTAB to End of Phase B | -6.70 ± 8.39 | -1.03 ± 11.2 |
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for attention + organization subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA method was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in WRAADDS Attention + Organization Subscale Score to End of Phase B | -1.47 ± 0.17 | -1.42 ± 0.22 |
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for hyperactivity + impulsivity subscale score ranges from 0-12, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From End of Phase A (Week 5 Visit) to End of Phase B (Week 11 Visit) in WRAADDS Hyperactivity + Impulsivity Subscale Score to End of Phase B | -1.27 ± 0.14 | -1.01 ± 0.19 |
WRAADDS is used to measure the severity of symptoms in adults with ADHD. This structured interview consists of 28 items in 7 psychopathologic domains, which were rated by a clinical expert on a 0 to 2-point Likert scale. The psychopathologic 7 domains are inattention (6 items), impulsivity (3 items), and hyperactivity (3 items), disorganization (5 items), temper (3 items), affective lability (4 items), and emotional over-reactivity (4 items). The scale rated individual items from 0 to 2 (0=not present, 1=mild, 2=clearly present). The score for temper + mood Lability + emotional over-reactivity subscale score ranges from 0-22, higher scores indicate worsening of symptoms. A negative change from Baseline indicates improvement. The ANCOVA model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Change From Baseline (End of Phase A) in WRAADDS Temper + Mood Lability + Emotional Over-reactivity Subscale Score to End of Phase B | -1.24 ± 0.20 | -1.35 ± 0.26 |
The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The CGI-I is completed by the clinician and assesses the participant's improvement relative to the symptoms at Baseline. The Cochran-Mantel-Haenszel model was used for analysis.
| score on a scale | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Week 6 | 3.19 ± 0.81 | 3.12 ± 0.77 |
| Week 7 | 3.04 ± 0.88 | 3.08 ± 0.80 |
| Week 8 | 2.93 ± 0.96 | 2.88 ± 1.01 |
| Week 9 | 2.82 ± 1.02 | 2.81 ± 1.03 |
| Week 10 | 2.80 ± 0.99 | 2.76 ± 1.07 |
| Week 11 | 2.68 ± 1.06 | 2.69 ± 1.17 |
Response was defined as ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms.
| percentage of participants | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Week 6 | 15.0 | 12.8 |
| Week 7 | 24.2 | 24.4 |
| Week 8 | 28.8 | 33.3 |
| Week 9 | 35.9 | 41.0 |
| Week 10 | 37.9 | 44.9 |
| Week 11 | 45.1 | 50.0 |
Remission was defined as CAARS-O:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-O:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). An 18-item ADHD Symptoms Total Score consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales. The CAARS-O:SV was designed to measure a cross-section of ADHD-related symptoms and behaviors in adults using observer and self-report scales. Total ADHD Symptoms Score (18 items) consisted of the combined score for the inattentive symptoms and hyperactive/impulsive symptoms subscales and is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for a total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.
| percentage of participants | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Week 6 | 7.19 | 6.41 |
| Week 7 | 12.4 | 12.8 |
| Week 8 | 19.0 | 19.2 |
| Week 9 | 20.9 | 23.1 |
| Week 10 | 25.5 | 28.2 |
| Week 11 | 27.5 | 33.3 |
Response was defined as ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.
| percentage of participants | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Week 6 | 11.8 | 12.8 |
| Week 7 | 18.3 | 15.4 |
| Week 8 | 21.6 | 21.8 |
| Week 9 | 29.4 | 29.5 |
| Week 10 | 25.5 | 32.1 |
| Week 11 | 31.4 | 37.2 |
Remission was defined as CAARS-S:SV ADHD Symptoms Total Score (18 items) of ≤ 18 and a ≥ 30% reduction in CAARS-S:SV ADHD Symptoms Total Score (18 items) from end of Phase A (Week 5 visit). The CAARS-S:SV is a 30 items scale with 3 subscales inattention (9 items), hyperactivity-impulsivity (9 items), and ADHD index (12 items). Total ADHD Symptoms Score (18 items) consisted of the combined score for the Inattentive Symptoms and Hyperactive/Impulsive Symptoms subscales is scored on a 4-point scale from 0 (not at all; never) to 3 (very much, very frequently) for total score ranging from of 0 to 54, higher scores indicate worsening of symptoms. The Cochran-Mantel-Haenszel model was used for analysis.
| percentage of participants | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Week 6 | 8.50 | 7.69 |
| Week 7 | 12.4 | 12.8 |
| Week 8 | 15.7 | 15.4 |
| Week 9 | 20.9 | 20.5 |
| Week 10 | 20.9 | 19.2 |
| Week 11 | 24.2 | 25.6 |
Response was defined as a CGI-I score of 1 or 2 (very much improved or much improved). The CGI-I permits a global evaluation of the participant's improvement over time. The CGI-I is a 8-point scale ranging from 0 to 7 where 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse and 7=very much worse. The Cochran-Mantel-Haenszel model was used for analysis.
| percentage of participants | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant |
|---|---|---|
| Week 6 | 18.3 | 15.4 |
| Week 7 | 23.5 | 17.9 |
| Week 8 | 31.4 | 30.8 |
| Week 9 | 37.9 | 41.0 |
| Week 10 | 40.5 | 39.7 |
| Week 11 | 44.4 | 44.9 |
Collected over From first dose through 30 days after last dose of study drug (Up to approximately Week 15). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 0/733 (0%) | 0/733 (0%) | 440/733 (60%) |
| Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 0/155 (0%) | 0/155 (0%) | 32/155 (20.6%) |
| Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 0/80 (0%) | 2/80 (2.5%) | 25/80 (31.3%) |
| Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0/339 (0%) | 0/339 (0%) | 17/339 (5%) |
| Event | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/733 | 0/155 | 1/80 | 0/339 |
| Urinary tract infectionInfections and infestations | 0/733 | 0/155 | 1/80 | 0/339 |
| Event | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant |
|---|---|---|---|---|
| Decreased AppetiteMetabolism and nutrition disorders | 155/733 | 0/155 | 0/80 | 0/339 |
| HeadacheNervous system disorders | 128/733 | 11/155 | 10/80 | 0/339 |
| Dry MouthGastrointestinal disorders | 113/733 | 0/155 | 0/80 | 0/339 |
| InsomniaPsychiatric disorders | 85/733 | 0/155 | 0/80 | 0/339 |
| InsomniaPsychiatric disorders | 0/733 | 13/155 | 1/80 | 0/339 |
| IrritabilityGeneral disorders | 57/733 | 0/155 | 0/80 | 0/339 |
| Weight decreasedInvestigations | 47/733 | 5/155 | 6/80 | 0/339 |
| NauseaGastrointestinal disorders | 51/733 | 0/155 | 0/80 | 0/339 |
| DiarrhoeaGastrointestinal disorders | 0/733 | 3/155 | 5/80 | 0/339 |
| Upper respiratory tract infectionInfections and infestations | 0/733 | 5/155 | 5/80 | 0/339 |
Randomized Sample consisted of all participants who were randomized in Phase B. Phase A+ Sample consisted of all non-randomized participants who were Phase A Responders or Phase A Non-responders, and who continued on Stimulant + single-blind placebo beyond Week 5. As pre-specified in the protocol and statistical analysis plan (SAP) the data is reported for Phase B and Phase A+ participants.
| Age, Continuous(years) | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | Total |
|---|---|---|---|---|
| Mean | 36.0 (18.0 to 55.0) | 33.6 (18.0 to 55.0) | 33.6 (18.0 to 55.0) | 34.4 (18.0 to 55.0) |
| Sex: Female, Male(Participants) | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | Total |
|---|---|---|---|---|
| Female | 79 | 38 | 164 | 281 |
| Male | 76 | 42 | 175 | 293 |
| Ethnicity (NIH/OMB)(Participants) | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | Total |
|---|---|---|---|---|
| Hispanic or Latino | 19 | 10 | 48 | 77 |
| Not Hispanic or Latino | 136 | 69 | 288 | 493 |
| Unknown or Not Reported | 0 | 1 | 3 | 4 |
| Race (NIH/OMB)(Participants) | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 4 | 6 |
| Asian | 3 | 0 | 9 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 10 | 38 | 57 |
| White | 140 | 65 | 281 | 486 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 4 | 7 | 13 |
| CAARS-O:SV ADHD Symptoms Total Score (18 items)(score on a scale) | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | Total |
|---|---|---|---|---|
| Mean | 32.94 (24.00 to 47.00) | 33.99 (24.00 to 52.00) | 40.1 (30.00 to 54.00) | 35.67 (24.00 to 54.00) |
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
No publications or documents are linked to this record.
Ran from Mar 2010 to primary completion in Jun 2011, 15 months.
Results were first posted in Feb 2023, 11 years 7 months after primary completion. A results delay was requested in Oct 2012.
Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 15 months is above that.
Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Attention Deficit Disorder with Hyperactivity →
Otsuka Pharmaceutical Development & Commercialization, Inc. →